Drug updated on 4/16/2024
| Dosage Form | Injection (subcutaneous; 25 mcg, 50 mcg, 75 mcg, 100 mcg) |
| Drug Class | Parathyroid hormones |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
Summary
- Parathyroid hormone (Natpara) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
- A total of 3 systematic reviews/meta-analyses were reviewed, providing insights into the effectiveness and safety of Natpara for its indication.
- One review highlighted that continuous subcutaneous infusion of parathyroid hormone through a pump may be an effective, safe, and feasible option for chronic hypoparathyroidism patients who are refractory to standard therapy; this includes both adult and pediatric populations with postsurgical or genetic etiology.
- Another meta-analysis found no significant difference between recombinant human parathyroid hormone (PTH) replacement therapy using Natpara versus conventional treatment with active vitamin D in terms of serum calcium levels, urinary calcium levels or incidence of serious adverse events among chronic hypoparathyroid patients.
- The third review emphasized the lack of high-quality evidence regarding the use of Natpara along with calcium and vitamin D supplements specifically for managing post-thyroidectomy temporary and long-term hypoparathyrodism; it called out a need for further research focusing on clinically relevant outcomes in these patient groups.
- Overall, while some studies suggest potential benefits from PTH infusion via pumps or PTH replacement therapies like Natparain certain patient subsets such as those refractory to standard care,the current literature lacks robust comparative data against traditional treatments across broader population sets including post-surgery cases.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Natpara (parathyroid hormone) Prescribing Information. | 2020 | FDA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review. | 2023 | Endocrine |
| Parathyroid hormone replacement versus oral calcium and active vitamin d supplementation in hypoparathyroidism: a meta-analysis. | 2020 | Indian Journal of Endocrinology and Metabolism |
| Calcium, vitamin D or recombinant parathyroid hormone for managing postâthyroidectomy hypoparathyroidism. | 2019 | Cochrane Database of Systematic Reviews |